Piero Brambati Email & Phone Number

Jakarta, Indonesia

Greater Jakarta Area, Indonesia

Developed and helped to implement a radical turnaround plan to address the Group margin structure and transform the inefficient net operating cash cycle. Group EBIT moved from a 10 M USD loss in 2013 to a 40 M USD profit in 2020, headcount cut in half while top line grew at double digit CAGR and working capital days dropped by 40% Negotiated a minority equity injection from Quadria Capital, a leading Singapore based healthcare focused PE investor. Quadria Capital was instrumental to the cultural transformation of the company and achieved an attractive Cash on Cash return Facilitated the exit of Quadria Capital by conducting a dual track process (M&A/IPO) involving an auction with multiple financial and strategic bidders and a parallel IDX listing process. The deal resulted in no residual liabilities either for the Group or the controlling shareholder Listed the company on the IDX in Sep 2020Currently leading the Value Creation Plan (VCP) jointly developed with CVC, one of the leading global PE funds and a new minority shareholder in the Group, involving multiple work streams Built the Group in-licensing program from scratch to develop a portfolio of differentiated specialty RX pharma products across 6 focused TCs. 43 molecules signed up to date from multiple international partners, 16 already launched, 7 included in the 2021-2022 JKN e-catalogueRolled out SAP across all Group legal entities entirely replacing the previous legacy system. Completed the Group management accounting toolkit to effectively track and steer financial performanceDrove efficiencies in the Finance Department (headcount down from 190 to 70) by streamlining the organization and automating processes. Over the years appointed to also lead IT (cost base reduced by 1/3), Procurement (sourcing costs cut by 25%), BD (created in-licensing program) and OperationsHelped to build Imboost into the #1 vitamin and one of the most valuable healthcare brands in Indonesia

London (Feb '06-Feb '11); Hong Kong (Mar '11-Jan '13)

Part of the fundamental research team reporting to the Chief Investment Officer, Mr. LC Kvaal, managing assets in excess of USD 2 B invested in a concentrated (70-100 positions) long-short portfolio of global equitiesCovered as sole analyst the following sectors across all of fund’s geographies, particularly Asia-Pacific ex Japan and Europe: consumer (food retail, general retail, brands and luxury goods), travel (airlines, tour operators, cruising), healthcare (pharmaceuticals, med-tech, healthcare services)Partner in the Firm since 25 June 2007Appointed to establish Habrok’s Asia Pacific local research presence and open Habrok’s HK office

Milan Area, Italy

BCG Consumer Goods and Pharmaceuticals PracticeLed design of defense strategy against generics for a major multinational pharmaceutical client in the Italian market, developed a sophisticated pricing model to maximize the residual NPV of the products going off patent. Project showcased as a success at the Global BCG Pharmaceutical Practice Conference Supported a global UK-based pharmaceutical company in redefining its sales force's approach to doctors in the Italian market Assisted a leading US pharma client global R&D division in the post merger integration of a bolt on acquisition, including the divestiture of an anti-infective discovery site Helped the dominant UK food retailer to assess Italian market entry opportunities, investigating overall market attractiveness and potential acquisition targets Analyzed, on behalf of PE funds, a potential merger between two leading Italian department store operators Reviewed the distribution and channel strategy of a PE controlled Italian FMCG major Helped to redesign the sales associate training system for a F&B travel retail multinational

Parma Area, Italy

Global Manufacturing and Supply Division.In charge of multi-million GBP manufacturing capex projects

Mba, Finance, Distinction

Education record

International Exchange Programme Participant - 2003

Laurea (Msc), Mechanical Engineering, 110+/110